Johnson & Johnson seeks regulator’s approval for vaccine booster shots

*Johnson & Johnson (J&J) subsidiary Janssen Research & Development says it found that a booster of its COVID-19 Vaccine increases levels of protection for consumers that have received single-shot vaccine to 94 percent

Isola Moses | ConsumerConnect

Johnson & Johnson (J&J) has stated it applied to the US Food and Drug Administration (FDA) for emergency use authorisation (EUA) for booster shots of its COVID-19 Vaccine.

The boosters would be given to consumers aged 18 and older who had previously received the company’s vaccine, agency report said.

The drug maker submitted data from clinical trials, showing that when a booster was given six months after the single shot, antibody levels increased nine-fold one week after the booster and continued to climb to 12-fold higher four weeks after the booster.

Johnson & Johnson noted that the vaccine was generally well-tolerated when given as a booster or primary dose.

Dr. Mathai Mammen, a top executive at J&J subsidiary Janssen Research & Development, said: “Our clinical programme has found that a booster of our COVID-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent.”

Kindly Share This Story